5-Aminolevulinic Acid-Mediated Metronomic Photodynamic Therapy for Mouse Mammary Tumors

[ABSTRACT] [Background] Metronomic photodynamic therapy (mPDT) is a novel cancer treatment strategy that uses low-dose light delivery and photosensitizers. 5-aminolevulinic acid (5-ALA), a precursor of protoporphyrin IX (PpIX) was previously used to treat human colorectal and esophageal cancer cells...

Full description

Saved in:
Bibliographic Details
Published inYONAGO ACTA MEDICA Vol. 68; no. 2; pp. 114 - 122
Main Authors Osaki, Tomohiro, Shiomi, Hikaru, Nishimura, Takahiro, Sakanoue, Kei, Eguchi, Kazuhiro, Miyazono, Yutaka, Yamaguchi, Ryoichi, Fujita, Katsuhiko, Kuwata, Kenji, Kobayashi, Naoki, Goya, Tsuyoshi, Morii, Katsuyuki, Ota, Urara, Imazato, Hideo, Takahashi, Kiwamu, Ishizuka, Masahiro
Format Journal Article
LanguageEnglish
Published Japan Tottori University Medical Press 2025
YAM
Subjects
Online AccessGet full text
ISSN0513-5710
1346-8049
1346-8049
DOI10.33160/yam.2025.05.004

Cover

Abstract [ABSTRACT] [Background] Metronomic photodynamic therapy (mPDT) is a novel cancer treatment strategy that uses low-dose light delivery and photosensitizers. 5-aminolevulinic acid (5-ALA), a precursor of protoporphyrin IX (PpIX) was previously used to treat human colorectal and esophageal cancer cells. However, no study has evaluated the efficacy of 5-ALA-mPDT using light of different wavelengths. Therefore, we evaluated cytotoxicity induced by 5-ALA-PDT and the antitumor effect of 5-ALA-mPDT. [Methods] In an in vitro experiment, we evaluated the cytotoxicity induced by 5-ALA-PDT using several fluence rates of light-emitting diode (LED) at wavelengths of 532 and 620 nm. In an in vivo experiment, we evaluated the antitumor effect of 5-ALA-mPDT using a newly developed implantable device emitting 532 or 620 nm. Moreover, we used in silico simulations to compare the differences in the distribution of the accumulated singlet oxygen concentrations between 532 and 620 nm. [Results] In the in vitro experiment, the percentages of late apoptotic/Dead and Dead cells in the 542-nm groups irradiated at light intensities of 1 mW/cm2 were significantly higher than those of cells in the 620-nm group. In contrast, in the in vivo experiment, the antitumor effect of mPDT using an implantable organic light-emitting diode (OLED) at 620 nm was significantly higher than that of mPDT using OLED at 542 nm. [Conclusion] Considering the results of our in silico study, the antitumor effect of 5-ALA-mPDT may be dependent on the distribution range of the accumulated singlet oxygen concentration rather than the accumulated singlet oxygen concentration.
AbstractList [ABSTRACT] [Background] Metronomic photodynamic therapy (mPDT) is a novel cancer treatment strategy that uses low-dose light delivery and photosensitizers. 5-aminolevulinic acid (5-ALA), a precursor of protoporphyrin IX (PpIX) was previously used to treat human colorectal and esophageal cancer cells. However, no study has evaluated the efficacy of 5-ALA-mPDT using light of different wavelengths. Therefore, we evaluated cytotoxicity induced by 5-ALA-PDT and the antitumor effect of 5-ALA-mPDT. [Methods] In an in vitro experiment, we evaluated the cytotoxicity induced by 5-ALA-PDT using several fluence rates of light-emitting diode (LED) at wavelengths of 532 and 620 nm. In an in vivo experiment, we evaluated the antitumor effect of 5-ALA-mPDT using a newly developed implantable device emitting 532 or 620 nm. Moreover, we used in silico simulations to compare the differences in the distribution of the accumulated singlet oxygen concentrations between 532 and 620 nm. [Results] In the in vitro experiment, the percentages of late apoptotic/Dead and Dead cells in the 542-nm groups irradiated at light intensities of 1 mW/cm2 were significantly higher than those of cells in the 620-nm group. In contrast, in the in vivo experiment, the antitumor effect of mPDT using an implantable organic light-emitting diode (OLED) at 620 nm was significantly higher than that of mPDT using OLED at 542 nm. [Conclusion] Considering the results of our in silico study, the antitumor effect of 5-ALA-mPDT may be dependent on the distribution range of the accumulated singlet oxygen concentration rather than the accumulated singlet oxygen concentration.
Metronomic photodynamic therapy (mPDT) is a novel cancer treatment strategy that uses low-dose light delivery and photosensitizers. 5-aminolevulinic acid (5-ALA), a precursor of protoporphyrin IX (PpIX) was previously used to treat human colorectal and esophageal cancer cells. However, no study has evaluated the efficacy of 5-ALA-mPDT using light of different wavelengths. Therefore, we evaluated cytotoxicity induced by 5-ALA-PDT and the antitumor effect of 5-ALA-mPDT.BackgroundMetronomic photodynamic therapy (mPDT) is a novel cancer treatment strategy that uses low-dose light delivery and photosensitizers. 5-aminolevulinic acid (5-ALA), a precursor of protoporphyrin IX (PpIX) was previously used to treat human colorectal and esophageal cancer cells. However, no study has evaluated the efficacy of 5-ALA-mPDT using light of different wavelengths. Therefore, we evaluated cytotoxicity induced by 5-ALA-PDT and the antitumor effect of 5-ALA-mPDT.In an in vitro experiment, we evaluated the cytotoxicity induced by 5-ALA-PDT using several fluence rates of light-emitting diode (LED) at wavelengths of 532 and 620 nm. In an in vivo experiment, we evaluated the antitumor effect of 5-ALA-mPDT using a newly developed implantable device emitting 532 or 620 nm. Moreover, we used in silico simulations to compare the differences in the distribution of the accumulated singlet oxygen concentrations between 532 and 620 nm.MethodsIn an in vitro experiment, we evaluated the cytotoxicity induced by 5-ALA-PDT using several fluence rates of light-emitting diode (LED) at wavelengths of 532 and 620 nm. In an in vivo experiment, we evaluated the antitumor effect of 5-ALA-mPDT using a newly developed implantable device emitting 532 or 620 nm. Moreover, we used in silico simulations to compare the differences in the distribution of the accumulated singlet oxygen concentrations between 532 and 620 nm.In the in vitro experiment, the percentages of late apoptotic/Dead and Dead cells in the 542-nm groups irradiated at light intensities of 1 mW/cm2 were significantly higher than those of cells in the 620-nm group. In contrast, in the in vivo experiment, the antitumor effect of mPDT using an implantable organic light-emitting diode (OLED) at 620 nm was significantly higher than that of mPDT using OLED at 542 nm.ResultsIn the in vitro experiment, the percentages of late apoptotic/Dead and Dead cells in the 542-nm groups irradiated at light intensities of 1 mW/cm2 were significantly higher than those of cells in the 620-nm group. In contrast, in the in vivo experiment, the antitumor effect of mPDT using an implantable organic light-emitting diode (OLED) at 620 nm was significantly higher than that of mPDT using OLED at 542 nm.Considering the results of our in silico study, the antitumor effect of 5-ALA-mPDT may be dependent on the distribution range of the accumulated singlet oxygen concentration rather than the accumulated singlet oxygen concentration.ConclusionConsidering the results of our in silico study, the antitumor effect of 5-ALA-mPDT may be dependent on the distribution range of the accumulated singlet oxygen concentration rather than the accumulated singlet oxygen concentration.
Metronomic photodynamic therapy (mPDT) is a novel cancer treatment strategy that uses low-dose light delivery and photosensitizers. 5-aminolevulinic acid (5-ALA), a precursor of protoporphyrin IX (PpIX) was previously used to treat human colorectal and esophageal cancer cells. However, no study has evaluated the efficacy of 5-ALA-mPDT using light of different wavelengths. Therefore, we evaluated cytotoxicity induced by 5-ALA-PDT and the antitumor effect of 5-ALA-mPDT. In an experiment, we evaluated the cytotoxicity induced by 5-ALA-PDT using several fluence rates of light-emitting diode (LED) at wavelengths of 532 and 620 nm. In an experiment, we evaluated the antitumor effect of 5-ALA-mPDT using a newly developed implantable device emitting 532 or 620 nm. Moreover, we used simulations to compare the differences in the distribution of the accumulated singlet oxygen concentrations between 532 and 620 nm. In the experiment, the percentages of late apoptotic/Dead and Dead cells in the 542-nm groups irradiated at light intensities of 1 mW/cm were significantly higher than those of cells in the 620-nm group. In contrast, in the experiment, the antitumor effect of mPDT using an implantable organic light-emitting diode (OLED) at 620 nm was significantly higher than that of mPDT using OLED at 542 nm. Considering the results of our study, the antitumor effect of 5-ALA-mPDT may be dependent on the distribution range of the accumulated singlet oxygen concentration rather than the accumulated singlet oxygen concentration.
Author Hideo Imazato
Takahiro Nishimura
Yutaka Miyazono
Hikaru Shiomi
Urara Ota
Ryoichi Yamaguchi
Katsuyuki Morii
Kei Sakanoue
Kiwamu Takahashi
Tomohiro Osaki
Katsuhiko Fujita
Masahiro Ishizuka
Tsuyoshi Goya
Kazuhiro Eguchi
Naoki Kobayashi
Kenji Kuwata
Author_xml – sequence: 1
  givenname: Tomohiro
  surname: Osaki
  fullname: Osaki, Tomohiro
  organization: Joint Department of Veterinary Medicine, Faculty of Agriculture, Tottori University, Tottori 680-8553, Japan
– sequence: 2
  givenname: Hikaru
  surname: Shiomi
  fullname: Shiomi, Hikaru
  organization: Joint Department of Veterinary Medicine, Faculty of Agriculture, Tottori University, Tottori 680-8553, Japan
– sequence: 3
  givenname: Takahiro
  surname: Nishimura
  fullname: Nishimura, Takahiro
  organization: Graduate School of Engineering, Osaka University, Suita, Osaka 565-0871, Japan
– sequence: 4
  givenname: Kei
  surname: Sakanoue
  fullname: Sakanoue, Kei
  organization: Pleiades Technologies LLC, Fukuoka 814-0001, Japan
– sequence: 5
  givenname: Kazuhiro
  surname: Eguchi
  fullname: Eguchi, Kazuhiro
  organization: Pleiades Technologies LLC, Fukuoka 814-0001, Japan
– sequence: 6
  givenname: Yutaka
  surname: Miyazono
  fullname: Miyazono, Yutaka
  organization: Pleiades Technologies LLC, Fukuoka 814-0001, Japan
– sequence: 7
  givenname: Ryoichi
  surname: Yamaguchi
  fullname: Yamaguchi, Ryoichi
  organization: Kumamoto Industrial Research Institute, Kumamoto 862-0901, Japan, ||Institute for Materials Chemistry and Engineering, Kyushu University, Fukuoka 816-8580, Japan
– sequence: 8
  givenname: Katsuhiko
  surname: Fujita
  fullname: Fujita, Katsuhiko
  organization: Institute for Materials Chemistry and Engineering, Kyushu University, Fukuoka 816-8580, Japan
– sequence: 9
  givenname: Kenji
  surname: Kuwata
  fullname: Kuwata, Kenji
  organization: NIPPON SHOKUBAI CO., LTD., Osaka 541-0043, Japan
– sequence: 10
  givenname: Naoki
  surname: Kobayashi
  fullname: Kobayashi, Naoki
  organization: NIPPON SHOKUBAI CO., LTD., Osaka 541-0043, Japan
– sequence: 11
  givenname: Tsuyoshi
  surname: Goya
  fullname: Goya, Tsuyoshi
  organization: NIPPON SHOKUBAI CO., LTD., Osaka 541-0043, Japan
– sequence: 12
  givenname: Katsuyuki
  surname: Morii
  fullname: Morii, Katsuyuki
  organization: Nippon Shokubai Research Alliance Laboratories Osaka University, Osaka 565-0871, Japan
– sequence: 13
  givenname: Urara
  surname: Ota
  fullname: Ota, Urara
  organization: SBI Pharmaceuticals Co., Ltd., Tokyo 106-6013, Japan
– sequence: 14
  givenname: Hideo
  surname: Imazato
  fullname: Imazato, Hideo
  organization: SBI Pharmaceuticals Co., Ltd., Tokyo 106-6013, Japan
– sequence: 15
  givenname: Kiwamu
  surname: Takahashi
  fullname: Takahashi, Kiwamu
  organization: SBI Pharmaceuticals Co., Ltd., Tokyo 106-6013, Japan
– sequence: 16
  givenname: Masahiro
  surname: Ishizuka
  fullname: Ishizuka, Masahiro
  organization: SBI Pharmaceuticals Co., Ltd., Tokyo 106-6013, Japan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40432740$$D View this record in MEDLINE/PubMed
BookMark eNpVUclu2zAUJIoEjeP23lOhYy9yH3f5VBhBmgSIkRwc9EhQ4lPMQCJdLSn096VqdwMeuGDmbTOX5CzEgIR8oLDinCr4PNl2xYDJFaQA8YYsKBcqL0Csz8gCJOW51BQuyGXfvyQCl6DekguRXkwLWJBvMt-0PsQGX8fGB19lm8q7fIvO2wFdtsWhiyG2CXjcxyG6Kdj5s9tjZw9TVscu28axx2xr29Z2U7Yb29j178h5bZse35_uJXn6er27us3vH27urjb3eSUViNxiKa1Ax7CoAWldq0LqWpU1cuvWomZVyTRypWstS6VZoR1LswNymqiO8iWhx7pjONjph20ac-j8PIihYH6JZJJIZhbJQIqUvSRfjjmHsWzRVRiGzv7Ni9ab_5Hg9-Y5vhrKKAipdarw6VShi99H7AfT-r7CprEBkxiGM8p0IcSaJerHf5v96fLbgkS4ORIS6ivbxJB8QPMSxy4k5YzzbIrBPp9WAFUAm9cwQOl8MCbk7PGa_wRjx6Ej
ContentType Journal Article
Copyright 2025 Tottori University Medical Press.
2025 Tottori University Medical Press 2025
Copyright_xml – notice: 2025 Tottori University Medical Press.
– notice: 2025 Tottori University Medical Press 2025
CorporateAuthor Institute for Materials Chemistry and Engineering
NIPPON SHOKUBAI CO
Graduate School of Engineering
Kumamoto Industrial Research Institute
Kyushu University
Pleiades Technologies LLC
SBI Pharmaceuticals Co
Faculty of Agriculture
Tottori University
Osaka University
Joint Department of Veterinary Medicine
LTD
Nippon Shokubai Research Alliance Laboratories Osaka University
CorporateAuthor_xml – name: Graduate School of Engineering
– name: Nippon Shokubai Research Alliance Laboratories Osaka University
– name: Kyushu University
– name: NIPPON SHOKUBAI CO
– name: Tottori University
– name: LTD
– name: Joint Department of Veterinary Medicine
– name: Institute for Materials Chemistry and Engineering
– name: Kumamoto Industrial Research Institute
– name: Pleiades Technologies LLC
– name: Osaka University
– name: SBI Pharmaceuticals Co
– name: Faculty of Agriculture
DBID NPM
7X8
5PM
ADTOC
UNPAY
DOI 10.33160/yam.2025.05.004
DatabaseName PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle PubMed
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1346-8049
EndPage 122
ExternalDocumentID 10.33160/yam.2025.05.004
PMC12104577
40432740
di2yonag_2025_006802_004_0114_01224557109
Genre Journal Article
GroupedDBID ---
.55
.GJ
123
2WC
3O-
53G
7.U
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BKOMP
C1A
DIK
E3Z
EMOBN
F5P
FRP
GX1
HYE
JMI
JSF
JSH
KQ8
MOJWN
OK1
P2P
RJT
RPM
RZJ
TR2
W2D
X7M
NPM
7X8
5PM
ADTOC
UNPAY
ID FETCH-LOGICAL-c5604-aeb5a4ed2e8f0e1ff6857f6bfe3ad94f2cb27e367f75b67287d20430e31f68d13
IEDL.DBID UNPAY
ISSN 0513-5710
1346-8049
IngestDate Tue Aug 19 23:42:19 EDT 2025
Thu Aug 21 18:37:45 EDT 2025
Thu May 29 07:19:25 EDT 2025
Sat May 31 02:13:06 EDT 2025
Sun Sep 07 07:20:38 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords mouse
mammary tumor
organic light-emitting diode
5-aminolevulinic acid
metronomic photodynamic therapy
Language English
License 2025 Tottori University Medical Press.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5604-aeb5a4ed2e8f0e1ff6857f6bfe3ad94f2cb27e367f75b67287d20430e31f68d13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://proxy.k.utb.cz/login?url=https://www.jstage.jst.go.jp/article/yam/advpub/0/advpub_2025.05.004/_pdf
PMID 40432740
PQID 3212784492
PQPubID 23479
PageCount 9
ParticipantIDs unpaywall_primary_10_33160_yam_2025_05_004
pubmedcentral_primary_oai_pubmedcentral_nih_gov_12104577
proquest_miscellaneous_3212784492
pubmed_primary_40432740
medicalonline_journals_di2yonag_2025_006802_004_0114_01224557109
PublicationCentury 2000
PublicationDate 20250000
PublicationDateYYYYMMDD 2025-01-01
PublicationDate_xml – year: 2025
  text: 20250000
PublicationDecade 2020
PublicationPlace Japan
PublicationPlace_xml – name: Japan
PublicationTitle YONAGO ACTA MEDICA
PublicationTitleAlternate Yonago Acta Med
PublicationYear 2025
Publisher Tottori University Medical Press
YAM
Publisher_xml – name: Tottori University Medical Press
– name: YAM
SSID ssj0043506
ssib002483309
ssib023157403
ssib002483305
Score 2.3066547
Snippet [ABSTRACT] [Background] Metronomic photodynamic therapy (mPDT) is a novel cancer treatment strategy that uses low-dose light delivery and photosensitizers....
Metronomic photodynamic therapy (mPDT) is a novel cancer treatment strategy that uses low-dose light delivery and photosensitizers. 5-aminolevulinic acid...
SourceID unpaywall
pubmedcentral
proquest
pubmed
medicalonline
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 114
SubjectTerms Original
Title 5-Aminolevulinic Acid-Mediated Metronomic Photodynamic Therapy for Mouse Mammary Tumors
URI http://mol.medicalonline.jp/en/journal/download?GoodsID=di2yonag/2025/006802/004&name=0114-0122e
https://www.ncbi.nlm.nih.gov/pubmed/40432740
https://www.proquest.com/docview/3212784492
https://pubmed.ncbi.nlm.nih.gov/PMC12104577
https://www.jstage.jst.go.jp/article/yam/advpub/0/advpub_2025.05.004/_pdf
UnpaywallVersion publishedVersion
Volume 68
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1346-8049
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0043506
  issn: 0513-5710
  databaseCode: KQ8
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1346-8049
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0043506
  issn: 0513-5710
  databaseCode: DIK
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: Open access medical journals (GFMER)
  customDbUrl:
  eissn: 1346-8049
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0043506
  issn: 0513-5710
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1346-8049
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0043506
  issn: 0513-5710
  databaseCode: RPM
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ba9swFBZbCrswdusu3qV4sKeBHMeSLOdtYayUgUsfEtY9CVmXNFlihybuyH79jiQ3NNteBnuyhSUh6RzJ39HR-YTQe0O05UoVmBJDMOWpwhUgXVwwncNSqGzhebbL0_xkQr-cs_OOUmjdHaucAy6aGvdIpk0yX_W7Qexv5bIv9RU0FCz58CLAeGeeezOlfbHS9jY6yBnA8h46mJyejb65lZgNCGY8MBMQ6gh46TC4LAkZ5KmrN7lRz330YBm8JIGt4m_g888zlHfbeiW3P-RiceMHdfwIza-7Fs6lfE_aTZWon7-xPv6Xvj9GDzsYG49CsSfolqmfojtl56g_RF8ZHi1ndbMwV62PvYxHaqZx6S8GMToujduCdxHR8dlFs2n0tpYuMQ4kBzFA6bhs2rWJS-mj6-Jxu2wu18_Q5Pjz-NMJ7u5wwAqwFMXSVExSozNT2NQMrM0Lxm1eWUOkHlKbqSrjhuTcclblHOw37aJ1U0MGkFUPyHPUq5vavESxkpkiDj4BrKCAQ2SqSAFolBtTVVaSCH3cE5voZuNa6Fm2Bbtm6gdM-OtGMnhQ4axB4Z2LzOnHMELvriUtYJo534msDfRWEMeEX1A6zCL0IkherAIfiHAERWDcpxEq9nRil8FReO9_qWcXnsrb0bdRxnmEPuzUZ1cM7DOvnwJk3zXdtZ6--pfMr9E9lwq7Rm9Qb3PZmreAozbVkd_aOurmyS_pJhyj
linkProvider Unpaywall
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ba9swFBZbCrswdm_n3fBgTwM5jiVZztvCWCkDlz4krHsSsi5pssQOTdyR_fodSW5otr0M9mQLS0LSOZK_o6PzCaH3hmjLlSowJYZgylOFK0C6uGA6h6VQ2cLzbJen-cmEfjln5x2l0Lo7VjkHXDQ17pFMm2S-6neD2N_KZV_qK2goWPLhRYDxzjz3Zkr7YqXtbXSQM4DlPXQwOT0bfXMrMRsQzHhgJiDUEfDSYXBZEjLIU1dvcqOe--jBMnhJAlvF38Dnn2co77b1Sm5_yMXixg_q-BGaX3ctnEv5nrSbKlE_f2N9_C99f4wedjA2HoViT9AtUz9Fd8rOUf8MfWV4tJzVzcJctT72Mh6pmcalvxjE6Lg0bgveRUTHZxfNptHbWrrEOJAcxACl47Jp1yYupY-ui8ftsrlcP0eT48_jTye4u8MBK8BSFEtTMUmNzkxhUzOwNi8Yt3llDZF6SG2mqowbknPLWZVzsN-0i9ZNDRlAVj0gh6hXN7V5gWIlM0UcfAJYQQGHyFSRAtAoN6aqrCQR-rgnNtHNxrXQs2wLds3UD5jw141k8KDCWYPCOxeZ049hhN5dS1rANHO-E1kb6K0gjgm_oHSYRegoSF6sAh-IcARFYNynESr2dGKXwVF473-pZxeeytvRt1HGeYQ-7NRnVwzsM6-fAmTfNd21nr78l8yv0D2XCrtGr1Fvc9maN4CjNtXbbob8AkKxG5M
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=5-Aminolevulinic+Acid-Mediated+Metronomic+Photodynamic+Therapy+for+Mouse+Mammary+Tumors&rft.jtitle=Yonago+acta+medica&rft.au=Osaki%2C+Tomohiro&rft.au=Shiomi%2C+Hikaru&rft.au=Nishimura%2C+Takahiro&rft.au=Sakanoue%2C+Kei&rft.date=2025&rft.pub=YAM&rft.issn=0513-5710&rft.eissn=1346-8049&rft.volume=68&rft.issue=2&rft.spage=114&rft.epage=122&rft_id=info:doi/10.33160%2Fyam.2025.05.004&rft.externalDocID=PMC12104577
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0513-5710&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0513-5710&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0513-5710&client=summon